bioAffinity Technologies publishes clinical framework for CyPath Lung in nodule evaluation

bioAffinity Technologies, Inc.

White paper by CMO Gordon Downie proposes specialty-specific pathways for pulmonology, primary care, oncology using CyPath Lung.
CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV in high-risk patients with small nodules.
Company reports 7.78M shares outstanding, market cap ~$5.1M as of July 24, 2026.
CyPath Lung analyzes sputum for lung microenvironment, not blood-based, providing real-time information.
Complete white paper available at https://bit.ly/cypath-lung-whitepaper3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.